Email
Password
Remember meForgot password?
    Log in with Twitter
| Press Release

Liquid Biopsy Market Estimated to Perceive Value USD 17,300 Million At a CAGR of 28% By 2022: Asserts MRFR

PUNE, India, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Market Research Future published a cooked research report on “Global Liquid Biopsy Market Research Report - Forecast to 2022” – Market Analysis, Scope, Trends and Forecast to 2022.

Guardant Health, Inc., Trovagene, Inc., RainDance Technologies, Inc., Agena Bioscience Inc. Inc., Admera Health, Biocept, Inc., Circulogene Theranostics, Inivata Ltd., SAGA Diagnostics AB, and Exosome Diagnostics are some of the prominent players profiled in MRFR Analysis and are at the forefront of competition in the Global Market of Liquid Biopsy.

Liquid Biopsy Market - Overview

Liquid Biopsies is a kind of test that reduces the need for costly, risky, and painful tumour tissue biopsies and opens up a whole new class of diagnostic tests and fuels hopes of better treatment options for patients and which is why The Global Liquid Biopsy Market is not only growing with the rapid pace but also gaining prominence over the last few years.

According to a recent study report published by the Market Research Future, the Global Liquid Biopsy Market has been booming and expected to gain further prominence over the forecasting period. The market is anticipated to demonstrate a spectacular growth by 2022, surpassing its previous growth records in terms of value with a striking double digit CAGR during 2016 – 2022.  Global Liquid Biopsy Market is currently valued at $ 3950 million and will reach $ 17,372.28 million growing at a CAGR of 28%.

Liquid Biopsy is a comparatively painless and non-invasive technique which provides early real time high precision detection of diseases which could be used for monitoring and designing effective treatment strategies based on the real time molecular assessment for the progression of the disease. Due to this factor a large amount of market growth is attributed. Additionally, factors such as lifestyle changes and environmental factors such as rising investment in research and development and collaborations between companies and public organizations, rise in population, particularly geriatric population, rising expenditure on health etc. are fostering the market growth. The technique also has other advantages over traditional tissue biopsy such as potential applications to cardiovascular diseases, autoimmune diseases, etc.

Request a Sample Report @ https://www.marketresearchfuture.com/sample_request/710

However, the restraining factors that may pose a challenge to the market growth are the prohibitive costs associated with liquid biopsy and the differential awareness and availability between developing and the developed world. Also, not all cancer patients benefit from early detection as some cancers, such as brain cancer and prostate cancer, may lie dormant for many years. Further liquid biopsy is not non-invasive as can be seen in case of using spinal fluid as a sample.

Liquid Biopsy Market - Competitive Analysis

Characterized by the presence of several well-established and small players, the global market of Liquid Biopsy appears to be highly competitive. Well established players incorporate acquisition, collaboration, partnership, expansion, and product launch in order to gain competitive advantage in this market and to maintain their market position. The key players operating in the market compete based on pricing, product (Test) launch, technology launch, and reputation. Marketers employ a continuous improvement strategy to analyze and update tests, implementing improvements and launching new solutions to meet the changing needs of both patients and health care professionals.  These key players invest heavily in developing a pipeline of innovative tests to address unmet patient needs.  They strive to develop non-invasive, comprehensive and proven genomic test which helps match advanced-cancer patients to approved targeted therapies as well as drugs in clinical trials.  And to provide such a comprehensive liquid biopsy, they extensively collaborate on more scientific research.

Liquid Biopsy Market - Segments

Segmentation By Biomarker Type: Comprises of Circulating Tumour Cells (Ctcs), Circulating Tumour DNA (Ctdna), Extracellular Vesicles (Evs) and other biomarkers.

Segmentation By Application: Comprises of Cancer Therapeutic Application, Reproductive Health, and other therapeutic application.

Segmentation By Sample: Comprises of Blood, Urine, and others.

Segmentation By End Users: Comprises of Hospitals and Laboratories, Academic and Research Centres, and others.

Segmentation By Regions: Comprises of Geographical regions - North America, Europe, APAC and Rest of the World.

Circulating tumour cells (CTCs) segment dominates both in terms of market share as well as revenues, contributing approx. 55.48% of the revenue share of the liquid biopsy market.

On the basis of the therapeutic application, the segment for cancer will reflect the highest growth potential, with over 82.83% of the market share by revenues. However, the urine sample segment is anticipated to witness noticeable growth.

The market for liquid biopsy is dominated by North America and Europe and this trend will continue. Asia-Pacific market is the fastest growing market and is expected to grow at a CAGR of 29.7% during forecasted period.

Browse Report @ https://www.marketresearchfuture.com/reports/liquid-biopsy-market-710

Liquid Biopsy Global Market - Regional Analysis

Globally, North America is the largest market for Global Liquid Biopsy Market. Europe is the second-largest market for Global Liquid Biopsy Market. However, the developing regions market particularly Asia Pacific will be the fastest growing and will be the key to the future. North America accounted for the largest market share of 37.95% in 2016 accounting for a market value of 1,499.10 million in 2016. Asia pacific is the fastest growing market which is growing at a CAGR of 28.8%.

Browse Related Report

Polyp Biopsy Market Information, by type (colonoscopy, colposcopy-directed biopsy, esophagogastroduodenoscopy, laryngoscopy) by site of polyp (uterus, nose, sinuses, colon), by biopsy device (needle-based biopsy guns, biopsy needles, biopsy forceps) - Forecast to 2022

https://www.marketresearchfuture.com/reports/polyp-biopsy-market-1673

Needle Biopsy Market information: by type (fine-needle aspiration biopsy, core needle biopsy, vacuum-assisted biopsy, image-guided biopsy) by utility (disposable, reusable), by applications (tumor, infection, Inflammation, others) - Global Forecast till 2023

https://www.marketresearchfuture.com/reports/needle-biopsy-market-3830

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

+1 646 845 9312

Email: sales@marketresearchfuture.com 

Primary Logo